These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 18827351)

  • 1. Antimicrobial effects of drugs against multidrug-resistant Pseudomonas aeruginosa.
    Maeda K; Kobayashi Y; Oie S; Ishida S; Okano Y; Kobayashi T; Shikichi K; Mizuno H; Kamiya A
    Biol Pharm Bull; 2008 Oct; 31(10):1898-901. PubMed ID: 18827351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro antimicrobial effects of aztreonam, colistin, and the 3-drug combination of aztreonam, ceftazidime and amikacin on metallo-beta-lactamase-producing Pseudomonas aeruginosa.
    Oie S; Fukui Y; Yamamoto M; Masuda Y; Kamiya A
    BMC Infect Dis; 2009 Aug; 9():123. PubMed ID: 19664245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro effects of combinations of antipseudomonal agents against seven strains of multidrug-resistant Pseudomonas aeruginosa.
    Oie S; Uematsu T; Sawa A; Mizuno H; Tomita M; Ishida S; Okano Y; Kamiya A
    J Antimicrob Chemother; 2003 Dec; 52(6):911-4. PubMed ID: 14585851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
    Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
    Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo Pharmacodynamics of Colistin and Aztreonam Alone and in Combination against Multidrug-Resistant Pseudomonas aeruginosa.
    Yamagishi Y; Hagihara M; Kato H; Hirai J; Nishiyama N; Koizumi Y; Sakanashi D; Suematsu H; Nakai H; Mikamo H
    Chemotherapy; 2017; 62(2):105-110. PubMed ID: 27788502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vitro effects of a combination of antipseudomonal antibiotics against multi-drug resistant Pseudomonas aeruginosa.
    Oie S; Sawa A; Kamiya A; Mizuno H
    J Antimicrob Chemother; 1999 Nov; 44(5):689-91. PubMed ID: 10552987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [In vitro combined effects of double antibacterial drugs against multidrug-resistant Pseudomonas aeruginosa isolates: comparison among combinations of colistin, arbekacin, aztreonam, rifampicin and piperacillin].
    Nagaoka R; Ikawa K; Onodera M; Koba Y; Hara T; Joichi Y; Yokozaki M; Ohge H; Morikawa N
    Jpn J Antibiot; 2014 Jun; 67(3):167-74. PubMed ID: 25163250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-vitro efficacy of synergistic antibiotic combinations in multidrug resistant Pseudomonas aeruginosa strains.
    Dundar D; Otkun M
    Yonsei Med J; 2010 Jan; 51(1):111-6. PubMed ID: 20046523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colistin plus meropenem combination is synergistic in vitro against extensively drug-resistant Pseudomonas aeruginosa, including high-risk clones.
    Montero MM; Domene Ochoa S; López-Causapé C; VanScoy B; Luque S; Sorlí L; Campillo N; Padilla E; Prim N; Segura C; Pomar V; Rivera A; Grau S; Ambrose PG; Oliver A; Horcajada JP
    J Glob Antimicrob Resist; 2019 Sep; 18():37-44. PubMed ID: 31154007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.
    Sader HS; Huband MD; Castanheira M; Flamm RK
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069652
    [No Abstract]   [Full Text] [Related]  

  • 12. Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia.
    Henderson A; Tan E; McCarthy KL; Paterson DL
    Pathology; 2018 Dec; 50(7):748-752. PubMed ID: 30392710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy.
    Riou M; Carbonnelle S; Avrain L; Mesaros N; Pirnay JP; Bilocq F; De Vos D; Simon A; Piérard D; Jacobs F; Dediste A; Tulkens PM; Van Bambeke F; Glupczynski Y
    Int J Antimicrob Agents; 2010 Dec; 36(6):513-22. PubMed ID: 20926262
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Goodlet KJ; Nicolau DP; Nailor MD
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.
    Erdem I; Kucukercan M; Ceran N
    Chemotherapy; 2003 Dec; 49(6):294-7. PubMed ID: 14671429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro interaction of various antibiotic combinations recommended by Chinese consensus statement against carbapenems-resistant Pseudomonas aeruginosa.
    Ma W; Li J; Wang D; Yu C; Sun S
    Lett Appl Microbiol; 2019 Sep; 69(3):198-203. PubMed ID: 31236975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination testing of multidrug-resistant cystic fibrosis isolates of Pseudomonas aeruginosa: use of a new parameter, the susceptible breakpoint index.
    Milne KE; Gould IM
    J Antimicrob Chemother; 2010 Jan; 65(1):82-90. PubMed ID: 19861334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility.
    Shortridge D; Pfaller MA; Castanheira M; Flamm RK
    Microb Drug Resist; 2018 Jun; 24(5):563-577. PubMed ID: 29039729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro efficacy of various antibiotic combinations against Pseudomonas aeruginosa isolates.
    Nazli E; Zer Y; Eksi F
    J Int Med Res; 2015 Apr; 43(2):217-25. PubMed ID: 25547417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009.
    Master RN; Clark RB; Karlowsky JA; Ramirez J; Bordon JM
    Int J Antimicrob Agents; 2011 Oct; 38(4):291-5. PubMed ID: 21737249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.